Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration; Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms COVARIANT
- 27 Apr 2021 Planned End Date changed from 28 Feb 2020 to 28 Feb 2024.
- 27 Apr 2021 Planned primary completion date changed from 28 Feb 2020 to 28 Feb 2024.
- 17 Sep 2019 Status changed from not yet recruiting to recruiting.